Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
- PMID: 16180117
- DOI: 10.1007/s11095-005-6650-0
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition
Abstract
Purpose: The aim of this study is to derive and evaluate an equilibrium model of a previously developed general pharmacokinetic model for drugs exhibiting target-mediated drug disposition (TMDD).
Methods: A quasi-equilibrium solution to the system of ordinary differential equations that describe the kinetics of TMDD was obtained. Computer simulations of the equilibrium model were carried out to generate plasma concentration-time profiles resulting from a large range of intravenous bolus doses. Additionally, the final model was fitted to previously published pharmacokinetic profiles of leukemia inhibitory factor (LIF), a cytokine that seems to exhibit TMDD, following intravenous administration of 12.5, 25, 100, 250, 500, or 750 microg/kg in sheep.
Results: Simulations show that pharmacokinetic profiles display steeper distribution phases for lower doses and similar terminal disposition phases, but with slight underestimation at early time points as theoretically expected. The final model well-described LIF pharmacokinetics, and the final parameters, which were estimated with relatively good precision, were in good agreement with literature values.
Conclusions: An equilibrium model of TMDD is developed that recapitulates the essential features of the full general model and eliminates the need for estimating drug-binding microconstants that are often difficult or impossible to identify from typical in vivo pharmacokinetic data.
Similar articles
-
General Pharmacokinetic Features of Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Simulation-Based Study.J Clin Pharmacol. 2019 Mar;59(3):394-405. doi: 10.1002/jcph.1335. Epub 2018 Nov 2. J Clin Pharmacol. 2019. PMID: 30387863
-
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901. Expert Opin Drug Metab Toxicol. 2009. PMID: 19505189 Review.
-
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):463-475. doi: 10.1007/s10928-017-9533-1. Epub 2017 Jul 19. J Pharmacokinet Pharmacodyn. 2017. PMID: 28725976
-
Target-mediated drug disposition model for drugs that bind to more than one target.J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):323-46. doi: 10.1007/s10928-010-9163-3. Epub 2010 Jul 29. J Pharmacokinet Pharmacodyn. 2010. PMID: 20669044
-
Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.J Clin Pharmacol. 2017 Feb;57(2):137-150. doi: 10.1002/jcph.804. Epub 2016 Sep 6. J Clin Pharmacol. 2017. PMID: 27489162 Review.
Cited by
-
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.Front Pharmacol. 2022 Sep 26;13:974423. doi: 10.3389/fphar.2022.974423. eCollection 2022. Front Pharmacol. 2022. PMID: 36225583 Free PMC article.
-
Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.Pharm Res. 2013 Mar;30(3):655-69. doi: 10.1007/s11095-012-0894-2. Epub 2012 Dec 19. Pharm Res. 2013. PMID: 23250851
-
Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors.Br J Pharmacol. 2019 Jul;176(14):2593-2607. doi: 10.1111/bph.14684. Epub 2019 May 21. Br J Pharmacol. 2019. PMID: 30945265 Free PMC article.
-
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.J Pharmacokinet Pharmacodyn. 2009 Jun;36(3):199-219. doi: 10.1007/s10928-009-9118-8. Epub 2009 May 12. J Pharmacokinet Pharmacodyn. 2009. PMID: 19434483
-
Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.MAbs. 2021 Jan-Dec;13(1):1964935. doi: 10.1080/19420862.2021.1964935. MAbs. 2021. PMID: 34530672 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources